Literature DB >> 21368901

Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation.

M Diken1, S Kreiter, A Selmi, C M Britten, C Huber, Ö Türeci, U Sahin.   

Abstract

Even though it is known for more than one decade that antigen-encoding RNA can deliver antigenic information to induce antigen-specific immunity against cancer, the nature and mechanism of RNA uptake have remained enigmatic. In this study, we investigated the pharmacokinetics of naked RNA administered into the lymph node. We observed that RNA is rapidly and selectively uptaken by lymph node dendritic cells (DCs). Furthermore, in vitro and in vivo studies revealed that the efficient internalization of RNA by human and murine DCs is primarily driven by macropinocytosis. Selective inhibition of macropinocytosis by compounds or as a consequence of DC maturation abrogated RNA internalization and delivery of encoded antigens. Our findings imply that bioavailability of recombinant RNA vaccines in vivo highly depends on the density and the maturation stage of DCs at the administration site and are of importance for the design of RNA-based clinical immunotherapy protocols.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21368901     DOI: 10.1038/gt.2011.17

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  59 in total

1.  Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant.

Authors:  Jan Ole Kemnade; Mamatha Seethammagari; Priya Narayanan; Jonathan M Levitt; Alison A McCormick; David M Spencer
Journal:  Mol Ther       Date:  2012-03-20       Impact factor: 11.454

2.  New Techniques to Assess In Vitro Release of siRNA from Nanoscale Polyplexes.

Authors:  Bettina Krieg; Markus Hirsch; Erik Scholz; Lutz Nuhn; Ilja Tabujew; Heiko Bauer; Sandra Decker; Andriy Khobta; Manfred Schmidt; Wolfgang Tremel; Rudolf Zentel; Kalina Peneva; Kaloian Koynov; A James Mason; Mark Helm
Journal:  Pharm Res       Date:  2014-12-09       Impact factor: 4.200

3.  CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.

Authors:  Sandra Lazzaro; Cinzia Giovani; Simona Mangiavacchi; Diletta Magini; Domenico Maione; Barbara Baudner; Andrew J Geall; Ennio De Gregorio; Ugo D'Oro; Cecilia Buonsanti
Journal:  Immunology       Date:  2015-08-28       Impact factor: 7.397

4.  mRNA cap analogues substituted in the tetraphosphate chain with CX2: identification of O-to-CCl2 as the first bridging modification that confers resistance to decapping without impairing translation.

Authors:  Anna M Rydzik; Marcin Warminski; Pawel J Sikorski; Marek R Baranowski; Sylwia Walczak; Joanna Kowalska; Joanna Zuberek; Maciej Lukaszewicz; Elzbieta Nowak; Timothy D W Claridge; Edward Darzynkiewicz; Marcin Nowotny; Jacek Jemielity
Journal:  Nucleic Acids Res       Date:  2017-09-06       Impact factor: 16.971

5.  Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening.

Authors:  Alexandra G Orlandini von Niessen; Marco A Poleganov; Corina Rechner; Arianne Plaschke; Lena M Kranz; Stephanie Fesser; Mustafa Diken; Martin Löwer; Britta Vallazza; Tim Beissert; Valesca Bukur; Andreas N Kuhn; Özlem Türeci; Ugur Sahin
Journal:  Mol Ther       Date:  2018-12-18       Impact factor: 11.454

6.  Buffering capacity and size of siRNA polyplexes influence cytokine levels.

Authors:  Qixin Leng; Szu-Ting Chou; Puthupparampil V Scaria; Martin C Woodle; A James Mixson
Journal:  Mol Ther       Date:  2012-10-02       Impact factor: 11.454

Review 7.  Developing mRNA-vaccine technologies.

Authors:  Thomas Schlake; Andreas Thess; Mariola Fotin-Mleczek; Karl-Josef Kallen
Journal:  RNA Biol       Date:  2012-10-12       Impact factor: 4.652

Review 8.  An RNA toolbox for cancer immunotherapy.

Authors:  Fernando Pastor; Pedro Berraondo; Iñaki Etxeberria; Josh Frederick; Ugur Sahin; Eli Gilboa; Ignacio Melero
Journal:  Nat Rev Drug Discov       Date:  2018-09-07       Impact factor: 84.694

Review 9.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

Review 10.  A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

Authors:  Karl-Josef Kallen; Andreas Theß
Journal:  Ther Adv Vaccines       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.